Enanta Pharmaceuticals (ENTA) Q4 2024 Earnings
ENTA·Reported February 10, 2025·Before market open
Enanta Pharmaceuticals reported Q4 2024 revenue of $17.0M, missed analyst consensus of $17.2M by $290.3K. Diluted EPS came in at $-1.05, beat the $-1.16 consensus by $0.11.
Revenue
$17.0Mmissed by $290.3K
Consensus: $17.2MDiluted EPS
$-1.05beat by $0.11
Consensus: $-1.16
Financial Snapshot
Trailing eight quarters through Q4 2024
Q4 2024 Earnings FAQ
Common questions about Enanta Pharmaceuticals's Q4 2024 earnings report.
Enanta Pharmaceuticals (ENTA) reported Q4 2024 earnings on February 10, 2025 before market open.
Enanta Pharmaceuticals reported revenue of $17.0M and diluted EPS of $-1.05 for Q4 2024.
Revenue missed the consensus estimate of $17.2M by $290.3K. EPS beat the consensus estimate of $-1.16 by $0.11.
You can read the 10-Q periodic report (0000950170-25-018810) directly on SEC EDGAR. The filing index links above go to sec.gov.